Showing 21-30 of 126 Results
Jennifer R. Cochran
Shriram Chair of the Department of Bioengineering, Professor of Bioengineering and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsMolecular Engineering, Protein Biochemistry, Biotechnology, Cell and Tissue Engineering, Molecular Imaging, Chemical Biology
Steven M. Corsello
Assistant Professor of Medicine (Oncology)
BioMy laboratory research aims to 1) leverage phenotypic screening and functional genomics to determine novel anti-cancer mechanisms of small molecules, 2) develop new targeted therapy approaches in gastrointestinal cancer, and 3) build a comprehensive community resource for drug repurposing discovery.
Professor of Bioengineering and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur focus is on building computational models of complex biological processes, and using them to guide an experimental program. Such an approach leads to a relatively rapid identification and validation of previously unknown components and interactions. Biological systems of interest include metabolic, regulatory and signaling networks as well as cell-cell interactions. Current research involves the dynamic behavior of NF-kappaB, an important family of transcription factors.
Job and Gertrud Tamaki Professor of Chemistry
Current Research and Scholarly InterestsOur objective is to develop new biophysical methods to advance current understandings of cellular machinery in the complicated environment of living cells. Currently, we are focusing on four research areas: (1) Membrane curvature at the nano-bio interface; (2) Nanoelectrode arrays (NEAs) for scalable intracellular electrophysiology; (3) Electrochromic optical recording (ECORE) for neuroscience; and (4) Optical control of neurotrophin receptor tyrosine kinases.
Martha S. Cyert
Dr. Nancy Chang Professor
Current Research and Scholarly InterestsThe Cyert lab is identifying signaling networks for calcineurin, the conserved Ca2+/calmodulin-dependent phosphatase, and target of immunosuppressants FK506 and cyclosporin A, in yeast and mammals. Cell biological investigations of target dephosphorylation reveal calcineurin’s many physiological functions. Roles for short linear peptide motifs, or SLiMs, in substrate recognition, network evolution, and regulation of calcineurin activity are being studied.
Director, Metabolomics Knowledge Center
BioDr. Yuqin Dai is the Director of the Metabolomics Knowledge Center at Stanford ChEM-H. In this role, she collaborates with faculty in the development and execution of experiments aimed at measuring small molecule drug candidates, endogenous and exogenous metabolites in a variety of biomedical R&D contexts. In addition, she provides strategic vision, mentorship, and leadership in the development of new LC/MS analytical methodologies for metabolomics research, the Metabolomics Knowledge Center’s daily operation and growth.
Dr. Dai came to ChEM-H with 20 years of research, marketing and managerial experiences across biotech/pharma and analytical instrument industries. Prior to joining ChEM-H in January of 2020, Dr. Dai worked at Agilent managing strategic collaborations with key opinion leaders in academia and industry for metabolomics researches, driving new application marketing opportunities, and developing differential solutions to support new LC/MS and automation product introductions. Before Agilent, Dr. Dai led bioanalytical R&D teams and managed DMPK projects to support drug discovery and development programs at three biotech/pharm companies. She was also extensively involved in new technology assessment and implementation. Dr. Dai received her Ph.D. in analytical chemistry from the University of Alberta, Canada, where her research focused on the LC/MS and MALDI/MS instrumentation and method development for proteomics and small molecule applications.
Laura M.K. Dassama
Assistant Professor of Chemistry and of Microbiology and Immunology
BioLaura Dassama is a chemical biologist who uses principles from chemistry and physics to understand complex biological phenomenal, and to leverage that understanding for the modulation of biological processes. Her current research focuses on deciphering the molecular recognition mechanisms of multidrug transporters implicated in drug resistance, rational engineering and repurposing of natural products, and control of transcription factors relevant to sickle cell disease.
Joseph M. DeSimone
Sanjiv Sam Gambhir Professor of Translational Medicine, Professor of Chemical Engineering and, by courtesy, of Chemistry, of Materials Science and Engineering, and of Operations, Information and Technology at the Graduate School of Business
BioJoseph M. DeSimone is the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He holds appointments in the Departments of Radiology and Chemical Engineering with courtesy appointments in the Department of Chemistry and in Stanford’s Graduate School of Business.
The DeSimone laboratory's research efforts are focused on developing innovative, interdisciplinary solutions to complex problems centered around advanced polymer 3D fabrication methods. In Chemical Engineering and Materials Science, the lab is pursuing new capabilities in digital 3D printing, as well as the synthesis of new polymers for use in advanced additive technologies. In Translational Medicine, research is focused on exploiting 3D digital fabrication tools to engineer new vaccine platforms, enhanced drug delivery approaches, and improved medical devices for numerous conditions, with a current major focus in pediatrics. Complementing these research areas, the DeSimone group has a third focus in Entrepreneurship, Digital Transformation, and Manufacturing.
Before joining Stanford in 2020, DeSimone was a professor of chemistry at the University of North Carolina at Chapel Hill and of chemical engineering at North Carolina State University. He is also Co-founder, Board Chair, and former CEO (2014 - 2019) of the additive manufacturing company, Carbon. DeSimone is responsible for numerous breakthroughs in his career in areas including green chemistry, medical devices, nanomedicine, and 3D printing. He has published over 350 scientific articles and is a named inventor on over 200 issued patents. Additionally, he has mentored 80 students through Ph.D. completion in his career, half of whom are women and members of underrepresented groups in STEM.
In 2016 DeSimone was recognized by President Barack Obama with the National Medal of Technology and Innovation, the highest U.S. honor for achievement and leadership in advancing technological progress. He has received numerous other major awards in his career, including the U.S. Presidential Green Chemistry Challenge Award (1997); the American Chemical Society Award for Creative Invention (2005); the Lemelson-MIT Prize (2008); the NIH Director’s Pioneer Award (2009); the AAAS Mentor Award (2010); the Heinz Award for Technology, the Economy and Employment (2017); the Wilhelm Exner Medal (2019); the EY Entrepreneur of the Year Award (2019 U.S. Overall National Winner); and the Harvey Prize in Science and Technology (2020). He is one of only 25 individuals elected to all three branches of the U.S. National Academies (Sciences, Medicine, Engineering). DeSimone received his B.S. in Chemistry in 1986 from Ursinus College and his Ph.D. in Chemistry in 1990 from Virginia Tech.
Associate Professor of Biology
Current Research and Scholarly InterestsMy lab is interested in the relationship between cell death and metabolism. Using techniques drawn from many disciplines my laboratory is investigating how perturbation of intracellular metabolic networks can result in novel forms of cell death, such as ferroptosis. We are interested in applying this knowledge to find new ways to treat diseases characterized by insufficient (e.g. cancer) or excessive (e.g. neurodegeneration) cell death.
Associate Professor of Computer Science and, by courtesy, of Molecular and Cellular Physiology and of Structural Biology
Current Research and Scholarly InterestsMy lab’s research focuses on computational biology, with an emphasis on 3D molecular structure. We combine two approaches: (1) Bottom-up: given the basic physics governing atomic interactions, use simulations to predict molecular behavior; (2) Top-down: given experimental data, use machine learning to predict molecular structures and properties. We collaborate closely with experimentalists and apply our methods to the discovery of safer, more effective drugs.